These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 22761704)

  • 1. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer.
    Ademuyiwa FO; Bshara W; Attwood K; Morrison C; Edge SB; Karpf AR; James SA; Ambrosone CB; O'Connor TL; Levine EG; Miliotto A; Ritter E; Ritter G; Gnjatic S; Odunsi K
    PLoS One; 2012; 7(6):e38783. PubMed ID: 22761704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors.
    Sugita Y; Wada H; Fujita S; Nakata T; Sato S; Noguchi Y; Jungbluth AA; Yamaguchi M; Chen YT; Stockert E; Gnjatic S; Williamson B; Scanlan MJ; Ono T; Sakita I; Yasui M; Miyoshi Y; Tamaki Y; Matsuura N; Noguchi S; Old LJ; Nakayama E; Monden M
    Cancer Res; 2004 Mar; 64(6):2199-204. PubMed ID: 15026363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of NY-ESO-1 in Triple-Negative Breast Cancer Is Associated with Tumor-Infiltrating Lymphocytes and a Good Prognosis.
    Lee HJ; Kim JY; Song IH; Park IA; Yu JH; Gong G
    Oncology; 2015; 89(6):337-44. PubMed ID: 26413775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
    Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
    Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers.
    Chen YT; Ross DS; Chiu R; Zhou XK; Chen YY; Lee P; Hoda SA; Simpson AJ; Old LJ; Caballero O; Neville AM
    PLoS One; 2011 Mar; 6(3):e17876. PubMed ID: 21437249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.
    Tang D; Xu S; Zhang Q; Zhao W
    Med Oncol; 2012 Jun; 29(2):526-33. PubMed ID: 21519872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of tumor-associated antigens in breast cancer subtypes.
    Curigliano G; Bagnardi V; Ghioni M; Louahed J; Brichard V; Lehmann FF; Marra A; Trapani D; Criscitiello C; Viale G
    Breast; 2020 Feb; 49():202-209. PubMed ID: 31869767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer.
    Mischo A; Kubuschok B; Ertan K; Preuss KD; Romeike B; Regitz E; Schormann C; de Bruijn D; Wadle A; Neumann F; Schmidt W; Renner C; Pfreundschuh M
    Int J Cancer; 2006 Feb; 118(3):696-703. PubMed ID: 16094643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological and prognostic characteristics of triple- negative breast cancer (TNBC) in Chinese patients: a retrospective study.
    Li CY; Zhang S; Zhang XB; Wang P; Hou GF; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(6):3779-84. PubMed ID: 23886182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NY-ESO-1 protein expression in primary breast carcinoma and metastases: correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration.
    Theurillat JP; Ingold F; Frei C; Zippelius A; Varga Z; Seifert B; Chen YT; Jäger D; Knuth A; Moch H
    Int J Cancer; 2007 Jun; 120(11):2411-7. PubMed ID: 17294444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.
    Hamaï A; Duperrier-Amouriaux K; Pignon P; Raimbaud I; Memeo L; Colarossi C; Canzonieri V; Perin T; Classe JM; Campone M; Jézéquel P; Campion L; Ayyoub M; Valmori D
    PLoS One; 2011; 6(6):e21129. PubMed ID: 21747904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-testis antigen expression in triple-negative breast cancer.
    Curigliano G; Viale G; Ghioni M; Jungbluth AA; Bagnardi V; Spagnoli GC; Neville AM; Nolè F; Rotmensz N; Goldhirsch A
    Ann Oncol; 2011 Jan; 22(1):98-103. PubMed ID: 20610479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
    J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival.
    Shandiz FH; Shabahang H; Afzaljavan F; Sharifi N; Tavasoli A; Afzalaghaee M; Roshanzamir E; Pasdar A
    Asian Pac J Cancer Prev; 2016; 17(3):1347-50. PubMed ID: 27039770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.
    Szender JB; Papanicolau-Sengos A; Eng KH; Miliotto AJ; Lugade AA; Gnjatic S; Matsuzaki J; Morrison CD; Odunsi K
    Gynecol Oncol; 2017 Jun; 145(3):420-425. PubMed ID: 28392127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
    Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
    Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 expression and immunogenicity in esophageal cancer.
    Fujita S; Wada H; Jungbluth AA; Sato S; Nakata T; Noguchi Y; Doki Y; Yasui M; Sugita Y; Yasuda T; Yano M; Ono T; Chen YT; Higashiyama M; Gnjatic S; Old LJ; Nakayama E; Monden M
    Clin Cancer Res; 2004 Oct; 10(19):6551-8. PubMed ID: 15475443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence.
    Brown TA; Mittendorf EA; Hale DF; Myers JW; Peace KM; Jackson DO; Greene JM; Vreeland TJ; Clifton GT; Ardavanis A; Litton JK; Shumway NM; Symanowski J; Murray JL; Ponniah S; Anastasopoulou EA; Pistamaltzian NF; Baxevanis CN; Perez SA; Papamichail M; Peoples GE
    Breast Cancer Res Treat; 2020 Jun; 181(2):391-401. PubMed ID: 32323103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.